{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:53:33Z","timestamp":1760576013055,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"am","delay-in-days":343,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.clon.2022.11.012","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T07:30:05Z","timestamp":1671003005000},"page":"e245-e255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating Biomarkers in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus in the Pre-nephrectomy Setting"],"prefix":"10.1016","volume":"35","author":[{"given":"L.","family":"Mauge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Phan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Benhamouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Galy-Fauroux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Badoual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Topart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Thiery-Vuillemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Le Moulec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cessot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mejean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Tartour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Helley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"World kidney cancer factsheet","key":"10.1016\/j.clon.2022.11.012_bib1"},{"key":"10.1016\/j.clon.2022.11.012_bib2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2022.11.012_bib3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1634\/theoncologist.2016-0435","article-title":"Current clinical practice guidelines for the treatment of renal cell carcinoma: a systematic review and critical evaluation","volume":"22","author":"Bamias","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.clon.2022.11.012_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J\u00a0Natl Comprehen Cancer Netw"},{"key":"10.1016\/j.clon.2022.11.012_bib5","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.ejca.2012.01.027","article-title":"Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study","volume":"48","author":"Oudard","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2022.11.012_bib6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157488411797189433","article-title":"Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma","volume":"6","author":"Husseinzadeh","year":"2011","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.clon.2022.11.012_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ctrv.2012.12.015","article-title":"Differentiating mTOR inhibitors in renal cell carcinoma","volume":"39","author":"Pal","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clon.2022.11.012_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2022.11.012_bib9","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2022.11.012_bib10","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1002\/cncr.33033","article-title":"Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial","volume":"126","author":"Motzer","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2022.11.012_bib11","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2022.11.012_bib12","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2022.11.012_bib13","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1158\/1078-0432.CCR-18-1045","article-title":"Sunitinib prior to planned nephrectomy in metastatic renal cell carcinoma: angiogenesis biomarkers predict clinical outcome in the prospective phase II PREINSUT trial","volume":"24","author":"Mauge","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2022.11.012_bib14","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/bju.14581","article-title":"Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study","volume":"123","author":"Lebacle","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.clon.2022.11.012_bib15","first-page":"1","article-title":"FactoMineR: An R Package for Multivariate Analysis","volume":"25","author":"L\u00ea","year":"2008","journal-title":"J\u00a0Stat Soft"},{"year":"2014","series-title":"Multiple factor analysis by example using R","author":"Pag\u00e8s","key":"10.1016\/j.clon.2022.11.012_bib16"},{"key":"10.1016\/j.clon.2022.11.012_bib17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/wics.101","article-title":"Principal component analysis: principal component analysis","volume":"2","author":"Abdi","year":"2010","journal-title":"WIREs Comp Stat"},{"key":"10.1016\/j.clon.2022.11.012_bib18","first-page":"1","article-title":"a package for handling missing values in multivariate data analysis","volume":"70","author":"Josse","year":"2016","journal-title":"J\u00a0Stat Soft"},{"key":"10.1016\/j.clon.2022.11.012_bib19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/art.27186","article-title":"Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis","volume":"62","author":"Kokkonen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clon.2022.11.012_bib20","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2013.54.6911","article-title":"Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma","volume":"32","author":"Motzer","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2022.11.012_bib21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/bjc.2016.21","article-title":"Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma","volume":"114","author":"Voss","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2022.11.012_bib22","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-08-2057","article-title":"mTOR inhibitor RAD001 (everolimus) has antiangiogenic\/vascular properties distinct from a VEGFR tyrosine kinase inhibitor","volume":"15","author":"Lane","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2022.11.012_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/cells11010017","article-title":"Decrease of pro-angiogenic monocytes predicts clinical response to anti-angiogenic treatment in patients with metastatic renal cell carcinoma","volume":"11","author":"Oudard","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.clon.2022.11.012_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-5-32","article-title":"Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins","volume":"5","author":"DePrimo","year":"2007","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.clon.2022.11.012_bib25","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/bjc.2011.72","article-title":"Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors","volume":"104","author":"Farace","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2022.11.012_bib26","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1186\/s12885-021-08630-w","article-title":"Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma","volume":"21","author":"Powles","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2022.11.012_bib27","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1158\/1078-0432.CCR-20-4504","article-title":"Angiokines associated with targeted therapy outcomes in patients with non-clear cell renal cell carcinoma","volume":"27","author":"Armstrong","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2022.11.012_bib28","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1200\/JCO.2007.15.5416","article-title":"Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma","volume":"26","author":"Rini","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2022.11.012_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00280-013-2333-4","article-title":"Circulating proteins as potential biomarkers of sunitinib and interferon-\u03b1 efficacy in treatment-na\u00efve patients with metastatic renal cell carcinoma","volume":"73","author":"Harmon","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clon.2022.11.012_bib30","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.clon.2022.11.012_bib31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/ki.2009.552","article-title":"Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib","volume":"77","author":"Porta","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.clon.2022.11.012_bib32","doi-asserted-by":"crossref","first-page":"42149","DOI":"10.18632\/oncotarget.15011","article-title":"Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma","volume":"8","author":"Msaouel","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clon.2022.11.012_bib33","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(12)70241-3","article-title":"Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials","volume":"13","author":"Tran","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2022.11.012_bib34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/annonc\/mdr047","article-title":"A\u00a0cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma","volume":"23","author":"Zurita","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2022.11.012_bib35","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.3390\/cancers12071961","article-title":"The biological context of C-reactive protein as a prognostic marker in renal cell carcinoma: studies on the acute phase cytokine profile","volume":"12","author":"Aarstad","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clon.2022.11.012_bib36","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.urolonc.2015.07.010","article-title":"Interleukin-6 as an emerging regulator of renal cell cancer","volume":"33","author":"Kami\u0144ska","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clon.2022.11.012_bib37","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1186\/1471-2407-10-695","article-title":"Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib","volume":"10","author":"Gruenwald","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2022.11.012_bib38","doi-asserted-by":"crossref","first-page":"17069","DOI":"10.1073\/pnas.0708148104","article-title":"Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy","volume":"104","author":"Ebos","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clon.2022.11.012_bib39","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nm.2018","article-title":"Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth","volume":"15","author":"Albuquerque","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.clon.2022.11.012_bib40","doi-asserted-by":"crossref","first-page":"R1072","DOI":"10.1152\/ajpregu.00209.2018","article-title":"Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment","volume":"315","author":"Schito","year":"2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.clon.2022.11.012_bib41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/pcan.2011.63","article-title":"Regulation of soluble VEGFR-2 secreted by microvascular endothelial cells derived from human BPH","volume":"15","author":"Aweimer","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clon.2022.11.012_bib42","doi-asserted-by":"crossref","first-page":"jcs219352","DOI":"10.1242\/jcs.219352","article-title":"VEGFR2 survival and mitotic signaling depends on joint activation of associated C3ar1\/C5ar1 and IL-6R-gp130","volume":"132","author":"Hwang","year":"2019","journal-title":"J\u00a0Cell Sci"},{"key":"10.1016\/j.clon.2022.11.012_bib43","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1161\/ATVBAHA.110.204222","article-title":"Endothelial-specific transgenesis of TNFR2 promotes adaptive arteriogenesis and angiogenesis","volume":"30","author":"Luo","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clon.2022.11.012_bib44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jss.2004.05.007","article-title":"Expression and regulation of neuropilins and VEGF receptors by TNF-alpha in human endothelial cells","volume":"122","author":"Yang","year":"2004","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.clon.2022.11.012_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081176","article-title":"Attenuation of VEGFR-2 expression by sFlt-1 and low oxygen in human placenta","volume":"8","author":"Nevo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clon.2022.11.012_bib46","doi-asserted-by":"crossref","first-page":"C1162","DOI":"10.1152\/ajpcell.00533.2008","article-title":"Chronic hypoxia attenuates VEGF signaling and angiogenic responses by downregulation of KDR in human endothelial cells","volume":"296","author":"Olszewska-Pazdrak","year":"2009","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.clon.2022.11.012_bib47","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.bbrc.2010.12.057","article-title":"Hypoxia differentially regulates VEGFR1 and VEGFR2 levels and alters intracellular signaling and cell migration in endothelial cells","volume":"404","author":"Ulyatt","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clon.2022.11.012_bib48","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1582-4934.2009.00941.x","article-title":"A\u00a0systems biology perspective on sVEGFR1: its biological function, pathogenic role & therapeutic use","volume":"14","author":"Wu","year":"2010","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.clon.2022.11.012_bib49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5387\/fms.2018-15","article-title":"Interleukin-6 induces drug resistance in renal cell carcinoma","volume":"64","author":"Ishibashi","year":"2018","journal-title":"Fukushima J Med Sci"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655522005453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655522005453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:52:16Z","timestamp":1760543536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655522005453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0936655522005453"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2022.11.012","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating Biomarkers in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus in the Pre-nephrectomy Setting","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2022.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}